# Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

> clinical trial · VERIFIED · 2026-07-08

Status: ACTIVE_NOT_RECRUITING · Sponsor: Memorial Sloan Kettering Cancer Center · Condition: Renal Cancer

- Company: Memorial Sloan Kettering Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT01582204

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.